Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke

Starting the polypill: the use of a single age cut-off in males and females

(2016) Nicholas J Wald et al.   JOURNAL OF MEDICAL SCREENING

Discounting financial costs and health benefits in public health programmes

(2016) Nicholas J Wald et al.   JOURNAL OF MEDICAL SCREENING

Erratum to: Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example

(2015) Nicholas J. Wald et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example

(2014) Nicholas J. Wald et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations

(2012) Judith A. Finegold et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Randomized Polypill Crossover Trial in People Aged 50 and Over

(2012) David S. Wald et al.   PLoS One

Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach

(2011) David S. Wald et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

Discounting the Value of Life

(2011) Nicholas J Wald et al.   JOURNAL OF MEDICAL SCREENING

Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age

(2011) Nicholas J. Wald et al.   PLoS One

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population

(2011) P. F. van Gils et al.   BMJ Open

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Cost of stroke in the United Kingdom

(2009) O. Saka et al.   AGE AND AGEING

The NICE Cost-Effectiveness Threshold

(2008) Christopher McCabe et al.   PHARMACOECONOMICS